Brief: Active Biotech says new data from the phase 2 Legato-HD study will be presented at HSG 2018
08/11/2018 12:18
Nov 8 (Reuters) - Active Biotech AB ACTI.ST :
* REG-ACTIVE BIOTECH: NEW DATA FROM THE PHASE 2 LEGATO-HD
STUDY
WILL BE PRESENTED AT HSG 2018
* IN ADDITION TO PREVIOUSLY PRESENTED DATA ON
PRIMARY AND SECONDARY ENDPOINTS AND SAFETY PROFILE, RESULTS FOR
EXPLORATORY ENDPOINTS WILL BE PRESENTED
* DATA FOR Q-MOTOR, A SENSITIVE, STANDARDIZED
RATE-INDEPENDENT AND UNBIASED MEASURE, REVEALED NOMINAL
IMPROVEMENT ON MOTOR COORDINATION IN PATIENTS TREATED WITH
LAQUINIMOD
* THESE DATA TOGETHER WITH THE STRONG TREATMENT EFFECT ON
BRAIN
VOLUME LOSS PROPOSE A CENTRAL EFFECT OF LAQUINIMOD IN THE
LEGATO-HD STUDY
* ADDITIONAL ANALYSIS OF THE STUDY IS ONGOING AND FURTHER
RESULTS
WILL BE PRESENTED AT UPCOMING SCIENTIFIC MEETINGS
Source text for Eikon: ID:nGNEDprdd
Further company coverage: ACTI.ST
(Stockholm Newsroom)
((stockholm.newsroom@thomsonreuters.com; +46 (0)8-700 10 10;))